Clinical TrialJul 16, 2026, 08:49 AM
Artelo Biosciences' ART26.12 Shows Promise in OA Pain
AI Summary
Artelo Biosciences announced new preclinical data for ART26.12, its selective FABP5 inhibitor, demonstrating its therapeutic potential for osteoarthritis (OA) pain. In studies, ART26.12 significantly reduced OA-associated pain behaviors, comparable to naproxen, but with significantly less stomach tissue damage. These findings suggest a novel mechanism of action and an improved gastrointestinal safety profile. The company plans to commence enrollment for a clinical multiple ascending repeat dose study in healthy volunteers during the fourth quarter of this year.
Key Highlights
- ART26.12 significantly reduced osteoarthritis-associated pain behaviors in preclinical studies.
- Efficacy of ART26.12 was comparable to naproxen, a widely prescribed NSAID.
- ART26.12 exhibited significantly less stomach tissue damage compared to naproxen.
- The data supports ART26.12 as a potential differentiated, non-opioid pain therapy.
- Osteoarthritis affects more than 30 million Americans, highlighting a significant market.
- Enrollment for a clinical multiple ascending repeat dose study of ART26.12 is anticipated in Q4 this year.
Price Impact
More from ARTL